[go: up one dir, main page]

WO2024239571A1 - Polynucléotide pour inhiber syn2a, exosome le contenant et son utilisation - Google Patents

Polynucléotide pour inhiber syn2a, exosome le contenant et son utilisation Download PDF

Info

Publication number
WO2024239571A1
WO2024239571A1 PCT/CN2023/134677 CN2023134677W WO2024239571A1 WO 2024239571 A1 WO2024239571 A1 WO 2024239571A1 CN 2023134677 W CN2023134677 W CN 2023134677W WO 2024239571 A1 WO2024239571 A1 WO 2024239571A1
Authority
WO
WIPO (PCT)
Prior art keywords
syn2a
polynucleotide
exosomes
treatment
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2023/134677
Other languages
English (en)
Chinese (zh)
Inventor
朱铃强
刘丹
沈细亚
高博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ev Medical Co Ltd
Original Assignee
Suzhou Ev Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ev Medical Co Ltd filed Critical Suzhou Ev Medical Co Ltd
Publication of WO2024239571A1 publication Critical patent/WO2024239571A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • the embodiments of the present invention relate to the field of biomedicine, and in particular to polynucleotides for inhibiting syn2a, exosomes containing the same, and uses thereof.
  • Post-traumatic stress disorder is a psychiatric disorder that is mainly caused by intense trauma in individuals, and the symptoms can last for months or decades. Moreover, PTSD often coexists with other psychiatric disorders, such as depression and suicidal thoughts. Therefore, the treatment of PTSD is more urgent.
  • the most commonly used method in clinical practice is exposure therapy under the guidance of psychologists or psychiatrists, but this process is inefficient and it may take a long treatment process to overcome this painful memory.
  • drug therapies such as antidepressants, such as SSRI drugs fluoxetine (Prozac) and paroxetine (Paxil), which are effective in treating some symptoms of PTSD, but such drugs have potential psychological dependence and addiction. Therefore, it is crucial to develop new and safe drugs for the treatment of post-traumatic stress disorder.
  • the object of the present invention is to provide a polynucleotide for inhibiting syn2a.
  • Another object of the present invention is to provide exosomes.
  • Another object of the present invention is to provide a pharmaceutical composition.
  • Another object of the present invention is to provide a method for preventing, treating and/or assisting in treating post-traumatic stress disorder.
  • the present invention provides a first aspect of an isolated polynucleotide.
  • the polynucleotide is selected from any one of the following:
  • the second aspect of the present invention provides a small nucleic acid molecule containing the polynucleotide described in the first aspect of the present invention, wherein the small nucleic acid molecule is siRNA, siRNA precursor, dsRNA, shRNA, miRNA or small interfering RNA.
  • the fourth aspect of the present invention provides a pharmaceutical composition, comprising: the polynucleotide described in the first aspect of the present invention/the small nucleic acid molecule described in the second aspect of the present invention/the exosomes described in the third aspect of the present invention, and a pharmaceutically acceptable carrier.
  • the fifth aspect of the present invention provides a method for preventing, treating and/or assisting in the treatment of post-traumatic stress disorder, the method comprising the steps of: applying a therapeutically effective amount of the polynucleotide described in the first aspect of the present invention to the subject, or applying a therapeutically effective amount of the small nucleic acid molecule described in the second aspect of the present invention to the subject, or applying a therapeutically effective amount of the exosomes described in the third aspect of the present invention to the subject, or applying a therapeutically effective amount of the pharmaceutical composition described in the fourth aspect of the present invention to the subject.
  • the present invention provides the use of the exosomes described in the third aspect of the present invention for:
  • the ninth aspect of the present invention provides a method for preparing exosomes containing the polynucleotide according to the first aspect of the present invention, the method comprising the steps of:
  • Original exosomes are obtained, and then the polynucleotides described in the first aspect of the present invention are introduced into the original exosomes to obtain exosomes containing the polynucleotides described in the third aspect of the present invention.
  • the polynucleotide described in the first aspect of the present invention is introduced into the original exosomes by electrotransduction or chemical transduction.
  • the raw exosomes are obtained by treating cells with an ECS reagent.
  • the present invention has at least the following advantages:
  • the present invention provides a syn2a siRNA sequence, which can be used as a syn2a inhibitor for the prevention/treatment/adjuvant treatment of post-traumatic stress disorder (PTSD);
  • PTSD post-traumatic stress disorder
  • the present invention also provides an exosome loaded with a syn2a siRNA sequence, which can efficiently and tissue-specifically deliver the syn2a siRNA sequence to the target gene, inhibiting the expression of the target gene or its encoded protein.
  • a syn2a siRNA sequence which can efficiently and tissue-specifically deliver the syn2a siRNA sequence to the target gene, inhibiting the expression of the target gene or its encoded protein.
  • tail vein injection of the exosome-encapsulated syn2a siRNA can significantly reduce the average rigidity rate of ordinary C57 mice and fear memory refractory model mice. Therefore, the exosome drug is therapeutic and can effectively prevent and/or treat and/or assist in the treatment of PTSD.
  • Figure 1 shows the metabolic status of DiD-labeled exosomes in vivo after injection of DiD dye into the tail vein of mice according to an embodiment of the present invention, at 0, 2, and 8 hours;
  • Figure 2 is a comparison of Western blot validation results of syn2a/b protein in the cerebral cortex after the mouse tail vein was injected with control exosomes and si-syn2a exosomes according to an embodiment of the present invention, wherein Con is the control group, Si-syn2a is the experimental group, GAPDH is the internal reference, and the t-test was used for analysis.
  • the data are mean ⁇ standard error, **P ⁇ 0.01;
  • Figure 4 is a t-test analysis of the control group and the si-syn2a exosome group after tail vein injection of control RNA exosomes and si-syn2a exosomes in common C57BL/6J mice according to an embodiment of the present invention.
  • There is no significant difference in the freezing rate between the control group and the si-syn2a exosome group during the fear memory acquisition stage, while there is a significant change in the freezing rate of the fear memory extinction test (n 5), and the data are mean ⁇ standard error, *P ⁇ 0.05.
  • RNA interference is a new gene therapy technology with antiviral, anti-tumor and anti-inflammatory effects.
  • the application prospects in the medical field of diseases and so on are broad and have been rapidly developed.
  • Some RNA drugs have entered the clinical trial stage, opening up a new treatment approach for difficult and complicated diseases, especially multifactorial diseases such as cancer and viral infection.
  • small interfering RNA must be intracellular to play a role.
  • RNA molecules are negatively charged and sensitive to the nucleases widely present in the body, so it is not easy to be delivered to the target gene to achieve therapeutic effects.
  • exosomes containing the polynucleotide of the present invention as a drug for treating PTSD is a very novel, feasible and effective method.
  • the present invention relates to an isolated polynucleotide for inhibiting the expression of syn2a and its encoded protein.
  • a nucleic acid drug it can bind to the target gene syn2a to inhibit syn2a expression.
  • polynucleotide or “nucleic acid” refers to a nucleotide or nucleotide monomer sequence composed of naturally occurring bases, sugars and sugars (hubs). The term also includes a limited or replacement sequence containing a monomer or a portion thereof that does not exist in nature.
  • the polynucleotide sequence of the present invention can be a deoxyribonucleic acid sequence (DNA) or a ribonucleic acid sequence (RNA), and can contain natural bases of adenine, guanine, cytosine and uracil.
  • the polynucleotide is a polynucleotide whose ribonucleic acid sequence is a polynucleotide as shown in SEQ ID NO:1.
  • the polynucleotide is a polynucleotide whose ribonucleic acid sequence is a polynucleotide with a homology greater than 80% (preferably greater than 90%, further preferably greater than 95%, further preferably greater than 98%, and further preferably greater than 99%) compared to the sequence shown in SEQ ID NO:1.
  • the polynucleotide is a polynucleotide whose ribonucleic acid sequence is a polynucleotide formed by replacing, deleting or adding one or more nucleotides of the sequence shown in SEQ ID NO: 1.
  • the inventors designed a plurality of polynucleotide molecules, and after screening and verification, obtained the above polynucleotide sequence, which has the strongest ability to inhibit syn2a expression at the same dose.
  • the aforementioned SEQ ID NO: 1 CCCAGAAATGACCATGTGATA.
  • sequence identity As used herein, the terms “homology”, “sequence identity” and “percentage of identity” are used interchangeably and refer to the percentage of identical (i.e., identical) nucleotides or amino acids between two or more polynucleotides or polypeptides. Sequence identity between peptides. The nucleotide or amino acid sequences of polynucleotides or polypeptides are arranged, and the number of positions containing the same nucleotide or amino acid residue in the arranged polynucleotides or polypeptides is scored and compared with the number of positions containing different nucleotides or amino acid residues in the arranged polynucleotides or polypeptides.
  • Polynucleotides can be different at one position, for example, according to the presence of different nucleotides (i.e., substitutions or variations) or the absence of nucleotides (i.e., insertion or deletion of one or two nucleotides in a polynucleotide).
  • Polypeptides can be different at one position, for example, by containing amino acids (i.e., substitutions or variations) or the absence of amino acids (i.e., insertion of amino acids or the absence of amino acids in one or two polypeptides). Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of amino acid residues in the polynucleotide or polypeptide.
  • percent identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of nucleotides or amino acid residues in the polynucleotide or polypeptide, and then multiplying by 100.
  • the present invention also relates to a small nucleic acid molecule containing the above polynucleotide, and the small nucleic acid molecule can be at least one of siRNA, siRNA precursor, dsRNA, shRNA, miRNA or small interfering RNA.
  • RNAi RNA interference
  • dsRNA double-stranded RNA
  • RNAi RNA-mediated virus resistance
  • quelling RNA-mediated virus resistance
  • siRNA Small interfering RNA
  • Dicer an enzyme in the RNase III family that is specific for double-stranded RNA
  • siRNA is a major member of siRISC, which stimulates the rapid cleavage and degradation of target RNAs with complementary sequences, resulting in the silencing of target genes, and thus becomes a key component of RNAi.
  • Key functional molecules Given a specific gene target sequence, those skilled in the art can design and obtain siRNA targeting the target sequence by conventional methods.
  • siRNA precursor refers to an RNA molecule that can be processed in mammalian cells to produce siRNA, specifically, it is selectively processed by Dicer or other similar proteins to produce mature siRNA, thereby implementing RNAi.
  • miRNA is a class of non-coding single-stranded RNA molecules with a length of about 20-24 nucleotides encoded by endogenous genes, which participate in the expression regulation of a large number of genes in animals and plants. So far, more than 4,000 miRNA molecules have been found in animals, plants and viruses. Most miRNA genes exist in the genome in the form of single copies, multiple copies or gene clusters. Each miRNA can regulate multiple target genes, and several miRNAs can also participate in the regulation of the same gene together to form a complex regulatory network. It is speculated that miRNA regulates the expression of more than half of human genes.
  • miRNA There are many forms of miRNA, the most primitive of which is pri-miRNA; after pri-miRNA is processed by Drosha, it becomes pre-miRNA, i.e., miRNA precursor, with a length of about 50-90 nucleotides; after pre-miRNA is cleaved by Dicer enzyme, it becomes a mature miRNA of about 20-24 nucleotides.
  • MiRNA mainly inhibits the expression of target genes by inhibiting translation and accelerating the deadenylation of mRNA, and its mechanism is different from siRNA-mediated mRNA degradation.
  • siRNA small interfering RNA
  • shRNA double-stranded RNA
  • shRNA and “shRNA” are used interchangeably and are a special shRNA constructed with the precursor of human miR-26b as the backbone.
  • the shRNA comprises, from the 5' end to the 3' end, the following: (a) a 5' end flanking sequence region; (b) a 5' end pairing siRNA region; (c) a top loop region; (d) a 3' end pairing siRNA region, and the 5' end pairing siRNA region and the 3' end pairing siRNA region form a double-stranded region; (e) a 3' end flanking sequence region; the shRNA produces siRNA, and the nucleotide sequence of the siRNA corresponds to the 3' end pairing siRNA region or the 5' end pairing siRNA region.
  • shRNA is the abbreviation of short hairpin RNA.
  • shRNA consists of two short reverse complementary sequences separated by a top loop sequence, forming a hairpin structure.
  • the shRNA sequence is usually transcribed by the endogenous RNA polymerase III promoter, and 5-6 Ts are connected to the end of the shRNA sequence as the transcription terminator of RNA polymerase III.
  • shRNA can also be transcribed by the promoter of other RNA polymerases.
  • the present invention also relates to exosomes containing the above-mentioned polynucleotides.
  • exosome and “exosome” are used interchangeably and refer to vesicles with a diameter of 30 to 100 nm produced by cells and having a lipid bilayer membrane structure. Exosomes are secreted by living cells and naturally exist in body fluids, including blood, saliva, urine, cerebrospinal fluid and milk. They are released from cells by fusion of late endosomes with cell membranes in the cell endocytic system or directly through the cell membrane, and play an important role in intercellular signaling.
  • the exosomes contain a polynucleotide as shown in SEQ ID NO: 1. In one embodiment of the present invention, the exosomes contain a polynucleotide with a homology greater than 80% (preferably greater than 90%, further preferably greater than 95%, further preferably greater than 98%, and further preferably greater than 99%) compared to the sequence shown in SEQ ID NO: 1. In one embodiment of the present invention, the exosomes contain a polynucleotide formed by substitution, deletion or addition of one or more nucleotides of the sequence shown in SEQ ID NO: 1.
  • the exosomes may also be engineered, such as targeted modification, loading modification.
  • the purified exosomes are loaded with a polynucleotide of the present invention.
  • the present invention also relates to a method for preparing exosomes containing polynucleotides, comprising the steps of:
  • raw exosomes refer to exosomes obtained directly from cells without loading exogenous target sequences.
  • the method of obtaining raw exosomes can be carried out in a conventional manner in the art, such as using a commercially available exosome extraction kit and obtaining exosomes according to the instructions of the kit.
  • ECS Esosomoe Concentration Solution
  • the original exosomes were obtained by treating cells with the agent.
  • the polynucleotides of the present invention can be introduced into exosomes using conventional nucleic acid delivery methods in the art, that is, the target polynucleotide sequence is engineered and loaded into the exosomes.
  • the loading is divided into exogenous loading or endogenous loading.
  • Exogenous loading is to first purify the acquired exosomes, and then introduce the target polynucleotides into the purified exosomes by electrotransduction methods such as electroporation or chemical transduction.
  • Endogenous loading is to first transform the source cells, for example, by directly transfecting or co-incubating the target polynucleotides into the source cells, and then causing the source cells to produce exosomes to obtain exosomes containing the target polynucleotides.
  • the target polynucleotides are introduced into exosomes using an exogenous loading method to obtain exosomes containing the target polynucleotides.
  • the method for purifying exosomes is carried out in accordance with conventional methods in the art.
  • the crude exosome particles are purified using an Exosomoe Purification Filter (EPF column), centrifuged at 3000 g for 10 min at 4°C, and the liquid at the bottom of the EPF column is collected after centrifugation to obtain purified exosome particles.
  • EPF column Exosomoe Purification Filter
  • the present invention also relates to a pharmaceutical composition, comprising the polynucleotide of the present invention or the exosome of the present invention, and a pharmaceutically acceptable carrier.
  • the term "pharmaceutically acceptable carrier” may include one or more of a pharmaceutically acceptable excipient, a buffer, a stabilizer, or other substances known to those skilled in the art.
  • pharmaceutically acceptable carriers include, but are not limited to, one or more of water, saline, a buffer, an isotonic agent such as a sugar, a polyol, an auxiliary substance such as a wetting agent or an emulsifier, a preservative, and a combination thereof. Such materials should be nontoxic and should not interfere with the efficacy of the active ingredient at the dosage and concentration employed.
  • the pharmaceutical composition comprises a polynucleotide of the present invention and a nucleic acid delivery vector as a pharmaceutically acceptable carrier, examples of which include liposomes, biocompatible polymers (including natural polymers and synthetic polymers), lipoproteins, polypeptides, polysaccharides, lipopolysaccharides, artificial viral envelopes, metal particles, and bacteria, viruses (such as baculovirus, adenovirus and retrovirus), bacteriophages, cosmids, plasmids, fungal vectors and vectors commonly used in the art and described Other recombinant vectors for expression in various eukaryotic hosts.
  • a nucleic acid delivery vector examples of which include liposomes, biocompatible polymers (including natural polymers and synthetic polymers), lipoproteins, polypeptides, polysaccharides, lipopolysaccharides, artificial viral envelopes, metal particles, and bacteria, viruses (such as baculovirus, adenovirus and retrovirus), bacterioph
  • the present invention also relates to a method for preventing, treating and/or assisting in the treatment of post-traumatic stress disorder, comprising the steps of: applying a therapeutically effective amount of the above-mentioned polynucleotide to a subject, or applying a therapeutically effective amount of exosomes to a subject, or applying a therapeutically effective amount of a pharmaceutical composition to a subject.
  • the term "treat” refers to eradicating or ameliorating a disease or condition, or one or more symptoms associated with the disease or condition. In one embodiment, such symptoms are known to those skilled in the art to be associated with the disease or condition to be treated. In a specific embodiment, the term refers to minimizing the spread or worsening of a disease or condition by administering one or more preventive or therapeutic agents to a subject suffering from the disease or condition. In some embodiments, the term refers to administering a compound of the present invention after the onset of symptoms of a particular disease, with or without other additional active agents.
  • prevention refers to preventing the onset, recurrence or spread of a disease or condition, or one or more symptoms associated with the disease or condition.
  • the symptom is known to those skilled in the art to be associated with the disease or condition to be prevented.
  • the term refers to the administration of the polynucleotides or exosomes of the present invention in combination with or without other additional active agents before the onset of symptoms to patients at risk of suffering from the diseases or disorders described herein.
  • the term includes the inhibition and reduction of symptoms of a particular disease.
  • patients with a family history of a disease are specifically considered candidates.
  • patients with a history of recurrent symptoms are also potential candidates for prevention.
  • the term "prevention” can be used interchangeably with the term "prophylactic treatment”.
  • a "therapeutically effective amount" of a polynucleotide or exosome refers to an amount of the drug sufficient to provide a therapeutic effect in the treatment or management of a disease or disorder, or sufficient to delay or minimize one or more symptoms associated with the disease or disorder.
  • a therapeutically effective amount of a compound refers to an amount of a therapeutic agent that can provide a therapeutic effect in the treatment or management of a disease or disorder when used alone or in combination with other therapies.
  • the term "therapeutically effective amount” may include an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.
  • the term "subject" is defined herein to include animals, such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In a specific embodiment, the subject is a human.
  • oral, parenteral, inhalation spray, topical, rectal, nasal, oral, vaginal or via implanted reservoir administration can be selected.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the composition is administered orally, intraperitoneally or intravenously.
  • the mode of administration is intravenous injection.
  • the present invention also relates to the use of the above-mentioned polynucleotide, exosome or pharmaceutical composition for
  • the term “and/or” should be considered as a specific disclosure of each of the two specified features or components, with or without the other. Therefore, the term “and/or” used in phrases such as “A and/or B” herein is intended to include “A and B", “A or B”, “A” (alone) and “B” (alone). Similarly, the term “and/or” used in the term “A, B and/or C” is intended to cover the following aspects: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
  • exosomes were extracted and purified.
  • the specific steps are as follows:
  • ECS reagent Exosomoe Concentration Solution
  • the centrifuge tube was tightly capped and mixed by vortex oscillator for 1 min, and then placed at 4°C for 2 h; the centrifuge tube containing the mixed solution was taken out and centrifuged at 10000g for 60 min at 4°C, and the supernatant was discarded.
  • the precipitate was rich in exosome particles; 100 ⁇ L 1 ⁇ PBS was taken to evenly blow the centrifuged precipitate, and after it was evenly suspended in PBS, the resuspension was transferred to a new 1.5mL centrifuge tube; the 1.5mL centrifuge tube containing the resuspension was centrifuged at 12000g for 2 min at 4°C, and the supernatant was retained. The supernatant was rich in exosome particles.
  • the harvested crude exosome particles were transferred into the upper chamber of Exosomoe Purification Filter (EPF column), centrifuged at 3000 g for 10 min at 4°C, and the liquid at the bottom of the EPF column was collected after centrifugation. This liquid was the purified exosome particles.
  • EPF column Exosomoe Purification Filter
  • the purified exosomes obtained in Example 1 were labeled with fluorescent dyes.
  • the specific steps are as follows:
  • Exosome staining Add the dye working solution to the exosomes, cover the centrifuge tube tightly after adding the dye working solution, mix by vortexing for 1 min, and then incubate for 10 min. Add 1 mL of 1X PBS to the incubated exosome-dye complex and mix well. Extract the exosomes again according to the exosome extraction method to remove excess dye, take 100 ⁇ L of 1 ⁇ PBS to resuspend the precipitate, and the precipitate is the labeled exosomes.
  • siRNA is electroporated into exosomes labeled with fluorescent dyes.
  • the specific steps are as follows:
  • Example 2 The fluorescent dye-labeled exosomes obtained in Example 2 were taken, and 100 ⁇ g of si-syn2a was electroporated into the exosomes using an electroporation procedure.
  • the exosomes labeled with fluorescent dye obtained in Example 2 were taken, and 100 ⁇ g of other siRNA sequences designed by the inventors were sequentially electroporated into the exosomes using an electroporation procedure to obtain a control group.
  • the siRNA NC sequence is electroporated into exosomes to obtain a control group.
  • siRNA NC sequence (SEQ ID NO:2): TTCTCCGAACGTGTCACGT.
  • exosomes were injected into the brains of experimental animals to conduct behavioral experiments on cued fear conditioning memory extinction.
  • Example 3 The exosomes obtained in Example 3 were injected into mice by tail vein injection, and the distribution of exosomes in the body was observed at 0 hours, 2 hours and 8 hours by small animal in vivo imaging technology ( Figure 1). The inventors found that the exosomes had entered the brain at 2 hours and could last up to 8 hours.
  • 10 male 8-10 week wild-type mice were selected.
  • exosomes were injected into the tail vein 6 hours in advance (5 experimental groups and 5 control groups).
  • the mice were placed in the electric shock box.
  • the electric shock box scene was A, and the smell was low-concentration ethanol.
  • the first foot shock (0.8mA, 1s) and sound (80db, 4000hz, 30s) were paired, that is, 1s electric shock was performed 29s after the sound appeared, and the sound and electric shock ended at the same time.
  • the interval was 20s.
  • mice were taken out and put back into the cage 60s after the last training, and the stiffness rate of each mouse was recorded.
  • the mice were conditioned for fear memory on the second day.
  • exosomes were injected into the tail vein 6 hours in advance, and then fear memory extinction training was performed.
  • the mice were placed in the experimental box, and the scene of the experimental box was changed to scene B.
  • the odor was low-concentration acetic acid.
  • 14 cycles of sound stimulation (80dB, 4000Hz, 20s) were presented, without electric shock. The interval between two adjacent sounds was 20s. 60s after the last training, the mice were taken out of the experimental box and put back into the mouse cage, and the stiffness rate was recorded.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un polynucléotide pour inhiber la syn2a, un exosome le contenant, et une utilisation associée. La présente invention concerne une séquence d'ARNsi syn2a, qui peut être utilisée en tant qu'inhibiteur de syn2a pour prévenir/traiter/aider au traitement d'un trouble de stress post-traumatique (PTSD). La présente invention concerne également un exosome chargé d'une séquence d'ARNsi syn2a, et l'exosome peut délivrer efficacement la séquence d'ARNsi syn2a à un gène cible de manière spécifique du tissu, inhiber l'expression du gène cible ou d'une protéine codée du gène cible, avoir un effet de traitement significatif sur des souris modèles réfractaires à la mémoire de peur, et peut réduire de manière évidente la raideur moyenne des souris.
PCT/CN2023/134677 2023-05-22 2023-11-28 Polynucléotide pour inhiber syn2a, exosome le contenant et son utilisation Pending WO2024239571A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310575582.5 2023-05-22
CN202310575582.5A CN116814620A (zh) 2023-05-22 2023-05-22 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途

Publications (1)

Publication Number Publication Date
WO2024239571A1 true WO2024239571A1 (fr) 2024-11-28

Family

ID=88128394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/134677 Pending WO2024239571A1 (fr) 2023-05-22 2023-11-28 Polynucléotide pour inhiber syn2a, exosome le contenant et son utilisation

Country Status (2)

Country Link
CN (1) CN116814620A (fr)
WO (1) WO2024239571A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115747256B (zh) * 2022-10-27 2024-12-10 华中科技大学 一种创伤后应激障碍模型小鼠的构建及其应用
CN116814620A (zh) * 2023-05-22 2023-09-29 苏州志恒生物科技有限公司 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104173363A (zh) * 2013-05-28 2014-12-03 中国医学科学院药物研究所 一种腺苷化合物在制备防治应激障碍药物中的用途
CN106109449A (zh) * 2016-07-05 2016-11-16 中国人民解放军第三○九医院 小剂量丙泊酚在制备防治抗创伤后应激障碍产品中的用途
CN109633140A (zh) * 2018-12-19 2019-04-16 中国环境科学研究院 一种利用斑马鱼评价全氟化合物神经发育毒性的方法
CN116814620A (zh) * 2023-05-22 2023-09-29 苏州志恒生物科技有限公司 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104173363A (zh) * 2013-05-28 2014-12-03 中国医学科学院药物研究所 一种腺苷化合物在制备防治应激障碍药物中的用途
CN106109449A (zh) * 2016-07-05 2016-11-16 中国人民解放军第三○九医院 小剂量丙泊酚在制备防治抗创伤后应激障碍产品中的用途
CN109633140A (zh) * 2018-12-19 2019-04-16 中国环境科学研究院 一种利用斑马鱼评价全氟化合物神经发育毒性的方法
CN116814620A (zh) * 2023-05-22 2023-09-29 苏州志恒生物科技有限公司 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PULLAGURI NARASIMHA; GROVER POONAM; ABHISHEK SUMAN; RAJAKUMARA EERAPPA; BHARGAVA YOGESH; BHARGAVA ANAMIKA: "Triclosan affects motor function in zebrafish larva by inhibiting ache and syn2a genes", CHEMOSPHERE, PERGAMON PRESS, OXFORD., GB, vol. 266, 12 November 2020 (2020-11-12), GB , XP086436379, ISSN: 0045-6535, DOI: 10.1016/j.chemosphere.2020.128930 *

Also Published As

Publication number Publication date
CN116814620A (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
US20200368162A1 (en) Nucleic Acid-Based Therapy of Muscular Dystrophies
JP2020114821A (ja) 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸（ｓｉＮＡ）の全身性送達
JP2019519219A (ja) ハンチントン病治療組成物及び方法
WO2024239571A1 (fr) Polynucléotide pour inhiber syn2a, exosome le contenant et son utilisation
WO2023051822A1 (fr) Oligonucléotide de ciblage pour le traitement de maladies associées à pcsk9
CN110520408B (zh) 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
JP2023542211A (ja) 神経疾患を処置するための方法
CN107922947A (zh) 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂
Tang et al. Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3
JP2025016506A (ja) 二本鎖ｒｎａ及びその使用
WO2023104028A1 (fr) Traitement de maladie neurologique médiée par un arn non codant
KR20210039495A (ko) 피드백이 가능한 합성 유전자, 표적 시드 매치 카세트, 및 그 용도
US20240123034A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
WO2024131946A1 (fr) Molécule d'acide nucléique et son utilisation
EP4074826A1 (fr) Arnsi pour inhiber l'expression du gène htt, et précurseur et application de celui-ci
CN116832049A (zh) 一种清除衰老细胞的核酸药物、药物组合物及其制备方法和应用
KR20240042457A (ko) 표적외 효과가 감소된 변형된 소간섭 rna 분자
CN115137742A (zh) 一种用于治疗肥胖症的rna递送系统
WO2022105903A1 (fr) Arnsi pour le traitement de la fibrose hépatique et préparation d'administration associée
CN120478386B (zh) 一种用于预防、改善和/或治疗阿尔茨海默症的siRNA及其用途
US20240368252A1 (en) Novel compositions for neuroprotection and axon regeneration
US20240229031A9 (en) Microrna compositions and methods of use thereof for the treatment of nervous system dysfunction
WO2025113699A1 (fr) Pri-miarn et son utilisation
CN120053691A (zh) 含hiHeps来源的外泌体的药物组合物及其应用
WO2024251244A1 (fr) Polynucléotide, composition pharmaceutique et utilisation associée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23938238

Country of ref document: EP

Kind code of ref document: A1